Trial · NCT07913594
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT07913594, Phase 2, Not yet recruiting, Olivia Newton-John Cancer Research Institute
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma. Trials, record NCT07913594. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07913594
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
- NCT number
- NCT07913594
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 25 participants, estimated
- Lead sponsor
- Olivia Newton-John Cancer Research Institute
- Conditions
- Peripheral T-Cell Lymphoma Refractory
- Interventions
- Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide
- First posted
- 2026-11-03
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide | Up to 18 weeks. | Rate of complete response to up to 6 cycles of combination zilovertamab vedotin and lenalidomide as determined by first documented disease progression per Lugano response criteria. |
| Secondary | Number of participants who experienced an adverse event (AE) | Up to 110 days after the last dose of investigational product. | An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the investigational products, is also an AE. The number of participants who experienced an AE will be reported. |
| Secondary | Overall survival (OS) | Up to 33 months | As defined as the time from enrolment until death, due to any cause, will be reported. |
| Secondary | Duration of response | Up to 33 months | DOR, defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, will be reported. |
| Secondary | Progression Free Survival | Up to 33 months | PFS, defined as the time from enrolment to the first documented disease progression per Lugano response criteria as assessed by PET/CT or death due to any cause, whichever occurs first will be presented. |
| Secondary | Change from baseline of health related quality of life | Up to 9 months | EORTC-QLQ-C30 (baseline and end of treatment) and PRO-CTCAE (baseline and prior to each cycle of treatment and end of treatment) responses will be collected from participants to examine any changes in health related quality of life. |
| Other | Blood and tissue markers linked to treatment response and side effects | 2 years | Blood and tissue samples will be used for biomarker analysis, which will include but is not limited to: minimum residual disease (MRD) in blood using cfDNA assessments, tumour microenvironment, peripheral blood immune portrait correlate potential biomarkers with treatment responses and toxicity. |
| Other | Gut bacteria changes linked to treatment response and side effects | 2 years | Studying whether changes in gut bacteria are associated with how patients respond to treatment and their risk of side effects. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07913594
GET https://conductscience.org/api/trials/v1/NCT07913594/registered